Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Article in English | MEDLINE | ID: mdl-25303829

ABSTRACT

BACKGROUND AND OBJECTIVES: Within the German National Cohort (GNC) 100,000 adult women in Germany will be comprehensively interviewed and examined. While women's health is addressed in the basic interview, direct detection of cervicovaginal microbial colonisation or infection is not part of the examination protocol. In a pilot project the feasibility of female study participants of the GNC collecting a cervicovaginal lavage at home without having to involve a gynecologist or other medical personnel was thus investigated. The ability of the procedure to detect vaginal microbes and conditions including human papillomavirus (HPV), Chlamydia trachomatis and bacterial vaginosis (BV) were also explored. METHODS: This cross-sectional study was conducted in two study centers (Hamburg and Hanover) of the GNC during Pretest 2 in 2012 as an add-on module to the main program of the National Cohort. Participants were randomly selected through the population registration office. After providing written informed consent at the study center, participants self-collected a cervicovaginal lavage (Delphi Screener™) at home following written instructions. Participants mailed samples and acceptability questionnaires to the laboratory and the study center, respectively. Acceptability of self-sampling was categorized as consent, partial consent and rejection. The samples were analyzed by multiplex HPV genotyping for the presence of 27 mucosal HPV subtypes. To detect other pathogens "Sexually Transmitted Infection Profiling" (STIP) was used, a novel multiplex polymerase chain reaction (PCR) for various vaginally occurring pathogens/conditions coupled with subsequent bead-based Luminex(®) hybridization. Human beta-globin and DNA polymerase alpha (PolA) sequences were used as positive controls for the detection of human DNA during HPV detection and STIP, respectively. RESULTS: The participation based on the proportion of all women in Pretest 2 who could take part in the add-on Pretest 2 was 67.3 % (109 out of 162). The age of participants ranged from 20 to 69 years. The self-reported median duration of the collection of the lavage was 5 min. Analysis of the questionnaires (n = 108) revealed that the self-sampling of a cervicovaginal lavage was acceptable to 98 % of women (106 out of 108), and considered to be easy by 89 % (96 out of 108) as well as user-friendly by 96 % of the women (104 out of 108). Human beta-globin and PolA as markers for human DNA and sample quality were detected in all samples analyzed while HPV as a marker for pathogen detectability was identified in 18 out of 109 samples. Of the 107 samples tested with STIP as a second marker for pathogen detectability, 5 samples were excluded from statistical analyses on bacterial colonization because of signs in the laboratory results of the use of antibiotics. For the computation of the possible occurrence of bacterial vaginosis and candidiasis 7 and 8 samples, respectively, were excluded because of low signal intensities resulting in an evaluation of 95 or 94 samples, respectively. Ureaplasma parvum was detected in 22 out of 102 samples, BV in 14 out of 95 samples and candidiasis in 13 out of 94 samples. Chlamydia trachomatis was not detected in any sample. CONCLUSION: The feasibility study on cervicovaginal self-sampling indicates that this form of biosampling was very well accepted within the framework of the GNC and feasible in terms of pathogen detection. Its further application in the GNC would allow investigation of transience and persistence, or long-term effects of vaginal (co)infections and colonization.


Subject(s)
Chronic Disease/epidemiology , Papillomavirus Infections/diagnosis , Papillomavirus Infections/epidemiology , Patient Compliance/statistics & numerical data , Patient Preference/statistics & numerical data , Self-Examination/statistics & numerical data , Specimen Handling/statistics & numerical data , Adult , Aged , Chronic Disease/prevention & control , Cohort Studies , Epidemiologic Research Design , Feasibility Studies , Female , Germany/epidemiology , Home Care Services/statistics & numerical data , Humans , Middle Aged , Papillomavirus Infections/microbiology , Patient Preference/psychology , Population Surveillance/methods , Young Adult
2.
Vaccine ; 31(19): 2372-80, 2013 May 01.
Article in English | MEDLINE | ID: mdl-23518405

ABSTRACT

In Germany, vaccination against the most oncogenic HPV types 16/18 is recommended by the Standing Committee on Vaccination (STIKO) for 12-17 year old girls since March 2007. We developed a dynamic mathematical model for the natural history and transmission of HPV infections to estimate the impact of vaccination on incidence and mortality of cervical cancer and its pre-stages, and on anogenital warts. We focused on an extensive model calibration to epidemiologic data for all stages of the natural history model as well as on a detailed implementation of cervical cancer screening modalities in Germany. Our model predicts first a substantial reduction of cervical cancer incidence and mortality over the next 30 years, which is mainly attributable to an increase in screening participation in the 1990s and not to HPV vaccination, followed by a further reduction attributable to vaccination. Over the next 100 years, HPV vaccination will prevent approximately 37% of cervical cancer cases even if vaccination coverage is only 50% (as currently observed in Germany). Consideration of cross-protection results in a further reduction of approximately 7% of all cervical cancer cases for the bivalent and about 5% for the quadrivalent vaccine in our model. Vaccination of boys was only reasonable if moderate to high vaccination coverage in girls was not achieved. Strategies should be implemented in Germany to increase HPV vaccination coverage among girls thereby making better use of the demonstrated benefits of the vaccine.


Subject(s)
Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/administration & dosage , Uterine Cervical Neoplasms/mortality , Uterine Cervical Neoplasms/prevention & control , Vaccination , Adolescent , Child , Condylomata Acuminata/epidemiology , Condylomata Acuminata/immunology , Condylomata Acuminata/prevention & control , Cross Protection , Female , Forecasting , Germany/epidemiology , Human papillomavirus 16/immunology , Human papillomavirus 18/immunology , Humans , Incidence , Male , Models, Theoretical , Papillomavirus Infections/immunology , Uterine Cervical Neoplasms/immunology
3.
Epidemiol Infect ; 140(9): 1589-98, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22313789

ABSTRACT

In order to contain a measles outbreak in a German asylum-seekers' shelter, serological testing of all residents was performed, followed by selective vaccination of those with negative test results/not tested. In this paper we describe the outbreak epidemiologically and then compare the implemented strategy with a hypothetical mass vaccination of all individuals unvaccinated or with unknown vaccination status born after 1970 as recommended by the German Standing Committee on Vaccination in terms of potentially avoided cases, logistics, and costs. Three hundred (70%) residents participated in the serological testing, of which 39 (13%) were seronegative. In total, 144 individuals were eligible for vaccination, while a mass vaccination would have targeted 359 persons. However, serological testing was time- and personnel consuming and revealed several logistical problems. Its costs amounted to €90 000, double that of mass vaccination that additionally might have avoided three of the eight cases. Mass vaccination seems the preferred measure for measles outbreak control in such settings.


Subject(s)
Disease Outbreaks/prevention & control , Mass Vaccination , Measles Vaccine/therapeutic use , Measles/epidemiology , Measles/prevention & control , Models, Biological , Adolescent , Adult , Aged , Child , Child, Preschool , Disease Outbreaks/economics , Enzyme-Linked Immunosorbent Assay , Female , Germany/epidemiology , Germany/ethnology , Humans , Infant, Newborn , Male , Mass Vaccination/economics , Measles Vaccine/economics , Refugees , Seroepidemiologic Studies , Young Adult
5.
Article in German | MEDLINE | ID: mdl-19760369

ABSTRACT

Most countries in Western Europe have recommended human papillomavirus (HPV) vaccination for the prevention of cervical cancer. The burden of cervical cancer remains high worldwide with regional differences in incidence rates and mortality. Due to varying conditions in health care systems and nationwide data in the individual European countries, there are slightly different cervical cancer prevention strategies. There is an overall consensus to monitor the public health impact of HPV vaccines. Despite having different prevention strategies and vaccination recommendations in the individual European countries, consideration of how to evaluate and coordinate pan-European surveillance measures should be taken into account.


Subject(s)
Mass Vaccination/standards , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/administration & dosage , Practice Guidelines as Topic , Precancerous Conditions/prevention & control , Uterine Cervical Neoplasms/prevention & control , Europe , Female , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...